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ABSTRACT

UBE4B LEVELS DETERMINE THE EFFICACY OF EGFR AND STAT5
INHIBITORS IN TREATMENT RESISTANT NEUROBLASTOMA

David J. Savage, B.A.
Advisory Professor: Andrew Bean, Ph.D.
Neuroblastoma is the most common malignancy in infants. Overexpression of the
epidermal growth factor receptor (EGFR) in neuroblastoma tumors can result in enhanced
EGFR signaling, uncontrolled proliferation, and may provide a mechanism for chemotherapy
resistance. UBE4B, an E3/E4 ubiquitin ligase, ubiquitinates the EGFR and promotes its
lysosomal degradation ultimately attenuating EGFR signaling. Interestingly, the UBE4B gene
lies in a chromosomal region (1p36) whose loss is correlated with poor patient outcomes due
to inefficient EGFR degradation and enhanced cell proliferation. We examined whether
depletion of UBE4B in a chemoresistant neuroblastoma cell line would affect tumor responses
to drugs that specifically target selected proteins that are upregulated in the absence of UBE4B.
UBE4B depletion in a resistant neuroblastoma cell line resulted in a number of proteins whose
levels were altered, including an increase in EGFR and STAT5a levels. We observed that
treatment with Cetuximab, a therapeutic antibody targeting the EGFR, significantly inhibited
the proliferation of neuroblastoma cells depleted of UBE4B. Addition of a STAT5 inhibitor
potentiated the Cetuximab-induced inhibition of proliferation, reduced migration, and
enhanced apoptosis in UBE4B-depleted neuroblastoma cells more than either drug treatment
alone. Thus, screening resected patient tumors for 1p36 status and UBE4B levels may enable
a novel treatment strategy in which selected patients who have low UBE4B-expressing tumors
may benefit from simultaneously targeting multiple EGFR signaling pathways.
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CHAPTER 1 - Introduction

1.1 Characteristics, Incidence, and Prevalence of Neuroblastoma

Neuroblastoma is a malignant (1), embryonal tumor that arises from neural crestderived cells of the sympathetic nervous system (2). It is the most frequently diagnosed tumor
in the first year of life, and the most common extracranial solid tumor in children (3). The
disease can spread from the head to the pelvis, but in a majority of cases the tumor arises from
the adrenal medulla (Figure 1) (4, 5). Neuroblastoma represents about 8% of all childhood
cancers (3), and more than 600 new cases of neuroblastoma are diagnosed in the United States
annually (6). More than 70% of patients are diagnosed with neuroblastoma after metastasis has
occurred (7).

.
Figure 1. Full-body CT scan demonstrating common locations for
neuroblastoma
This figure demonstrates a computed tomography (CT) scan of a child showing an
1

adrenal mass near the spine where it crosses the midline axis of the body.
Hallett, Andrew and Heidi Traunecker. 2012. “A Review and Update on
Neuroblastoma.” Paediatrics and Child Health 22(3):103–7. Retrieved
(http://dx.doi.org/10.1016/j.paed.2011.08.005).
Used with permission from from Elsevier.
The symptoms of neuroblastoma can be quite variable and are dependent upon the
tumor site (8). Tumor compression on the spinal cord can lead to lower extremity paralysis,
thoracic tumors can cause a Horner’s syndrome (anhidrosis, miosis, and partial ptosis) of the
eye, liver tumors can cause abdominal swelling, metastasis to the bone marrow can cause
hematologic disorders, and adrenal medullary tumors can cause abnormal catecholamine
production (5). This pleiotropic set of symptoms and the rarity of the disease (3) can make it
challenging to detect.
The long-term prognosis for neuroblastoma worsens with increased age of the patient
at diagnosis (9). Patients who are diagnosed at ages older than 18 months, who either have a
metastasis or who have tumors with unfavorable histology, or NMYC oncogene amplification,
tend to have a worse prognosis (4, 10). In cases of neuroblastoma relapse, treatment options
are limited since these tumor cells can rapidly develop resistance to conventional
chemotherapeutics (11).

1.2 Stratification of Neuroblastoma’s Severity

Stratification of the severity of neuroblastoma requires assessing a number of factors.
These include the stage of disease (12), age of the patient, whether or not the NMYC oncogene
is amplified, histopathology of the tumor, and chromosome abnormalities (9, 13). One such
common abnormality is a loss of heterozygosity (LOH) in the 1p chromosomal region (Figure
2

2), which is associated with a decreased response to treatment, a lower event-free, and a lower
overall survival (14–16). Approximately one-third of neuroblastoma cases display deletions
within the 1p36 chromosomal region (14–17). One gene within this region whose deletion has
been shown to correlate with poor prognosis is the ubiquitin ligase UBE4B, which regulates
growth receptor protein trafficking in the endocytic pathway (18, 19).
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Figure 2. UBE4B on the 1p chromosome site
Deletions at the 1p36 chromosome site occur in one third of neuroblastomas. This is
the site of the ubiquitin ligase, UBE4B, a regulator of growth factor degradation in the
endocytic pathway.
Carén, H., A. Holmstrand, R. M. Sjöberg, and T. Martinsson. 2006. “The Two Human
Homologues of Yeast UFD2 Ubiquitination Factor, UBE4A and UBE4B, Are
Located in Common Neuroblastoma Deletion Regions and Are Subject to
Mutations in Tumours.” European Journal of Cancer 42(3):381–87.
Used with permission from from Elsevier.
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1.3 Conventional Treatment of Neuroblastoma and Long-term Prognosis

The treatment for neuroblastoma depends on the risk stratification of the patient.
Patients are divided into low, intermediate, and high-risk groups (13). Therapy is multi-modal
and may include observation, surgery, chemotherapy, radiotherapy, stem cell transplantation,
differentiation therapy, and/or immunotherapy (8). While patients with non-metastatic,
minimally invasive neuroblastoma may be disease-free following surgery alone, chemotherapy
is used for patients with invasive or metastatic disease (20). Frontline chemotherapeutics for
neuroblastoma are non-specific and affect non-cancerous cells as well (21). They function
through either inducing DNA damage or interfering with the mitotic spindle to interrupt cell
division (22). This induces cell death and acts in a greater degree on rapidly proliferating
neuroblastoma cells, but it can affect normal cells, too (23). This explains many of the common
late side effects of chemotherapy treatment such as hearing loss, pulmonary fibrosis, and
cardiotoxicity (24).
Frontline chemotherapy, also called induction chemotherapy, for high risk
neuroblastoma includes a combination of cisplatin, vincristine, carboplatin, etoposide, and
cyclophosphamide (25). Each of these agents works by a different mechanism of action to kill
cancer cells, but broadly they target either DNA replication or cell division to cause irreversible
damage leading to apoptosis (23).

Cisplatin, carboplatin (a cisplatin analog), and

cyclophosphamide act by alkylating DNA bases. Subsequently, DNA repair enzymes cause
DNA damage while attempting to repair the alkylation, which ultimately leads to cell death
(22). Vincristine binds to the protein tubulin to interfere with cell division in mitosis (26).
Etoposide is a topoisomerase II inhibitor that prevents DNA unwinding during replication,

5

leading to apoptotic cell death (27). A combination of drug agents in the frontline treatment
phase delays the onset of selective chemotherapy resistance (28). Thus, using a combination
of chemotherapy agents that act by different mechanisms to interfere with cell growth in the
initial phase of treatment can increase the likelihood of a neuroblastoma patient becoming
cancer free.
Beyond traditional cytotoxic chemotherapy, other treatments are used for high risk
patients. They may be treated with myeloablation followed by autologous stem cell transplant
for neuroblastoma that may have spread to the bone marrow (29). Subsequent possible
treatments include forced cell differentiation with 13-cis-retinoic acid or targeted anti-GD2
antibody therapy which triggers cytotoxicity through an immune response (25). Retinoic acid
is used to treat residual disease after myeloablative therapy, and acts to force growth arrest and
terminal maturation of neural tissue (30). The anti-GD2 antibody works by binding to
neuroblastoma cells, which overexpress the ganglioside GD2. This induces cell death through
complement-mediated cytotoxicity and activation of the immune response. (31). High risk
neuroblastoma patients often require more complex treatment approaches to effectively treat
their disease.
The long-term prognosis for neuroblastoma depends on a patient’s risk classification
and tumor stage at the time of initial diagnosis (26). Patients in the low risk category can
expect a 92% event-free survival and 96% probability of overall survival (32, 33). Patients at
intermediate risk disease have an overall survival rate of 80% (34, 35), while patients with high
risk disease have an event-free survival of less than 50% despite multimodal therapy (36, 37).
Thus, while clinical outcomes are good for low and intermediate risk patients, new treatment
strategies are needed for high risk patients to improve their outcomes.

6

1.4 Mechanisms of Neuroblastoma Chemotherapy Resistance

High risk patients with a tumor relapse have poor outcomes in part because of the
development of chemotherapy resistance (4, 38). Some common cellular resistance
mechanisms include decreased chemotherapy drug uptake (39), increased drug efflux (40),
increased DNA damage repair (41), failure of cell death pathways (42), and increased growth
factor receptor expression at the cell surface (Figure 3) (18). Amplification of the MYCN gene,
a poor prognostic indicator in neuroblastoma, upregulates ABC transporters in cell membranes
that promote efflux of chemotherapy drugs from cells (40, 43). Chemotherapy resistance may
also be promoted by growth factor receptors, like the epidermal growth factor receptor
(EGFR), which is increased in amounts in other neural cancers leading to conventional
chemotherapy resistance by enhancing proliferation (44). EGFR protein levels are high in
many in vitro neuroblastoma cell lines and patient tumor biopsies (1). There are many
mechanisms of resistance in neuroblastoma that affect drug uptake and cellular response to
chemotherapy, and increased growth factor-stimulated signaling may be another mechanism
of resistance.

7

Figure 3. Common chemotherapy resistance mechanisms in cancer
Diagram of common mechanisms of chemotherapy resistance in cancer. Aside from
increased growth factor signaling, these mechanisms lower the intracellular amount
of drug or change the intended protein targets such that effects on cell division,
DNA replication, or signaling pathways are not lethal. Modified from:
El-Awady, Raafat et al. 2017. “The Role of Eukaryotic and Prokaryotic ABC
Transporter Family in Failure of Chemotherapy.” Frontiers in Pharmacology
7(JAN):1–15.
1.5 EGFR and the Endocytic Pathway

The endocytic pathway internalizes membrane proteins and transports them for
recycling, transit to other intracellular compartments, or degradation (45). It is an important
regulator of EGFR-mediated signaling for the proliferation of neuroblastoma (46). EGFR may
be internalized at the plasma membrane, trafficked through the endocytic pathway, and sorted,
into a pathway that will result in its lysosomal degradation or will cause the receptor to be
recycled for reuse (47). There are five ligands known to bind EGFR: epidermal growth factor
(EGF), transforming growth factor alpha (TGF-α), amphiregulin, epiregulin, and betacellulin
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(48). These ligands may have different fates during the trafficking process, but EGF binding
enhances degradation of the receptor as a means of attenuating signaling (49).
Upon ligand binding, the EGFR dimerizes, which then triggers autophosphorylation of
the tyrosine residues in the cytoplasmic tail of the receptor to initiate endocytosis. Binding of
EGF or TGF-α specifically results in clathrin-mediated endocytosis (47). In this process,
clathrin adapter protein 2 (AP2) protein complexes are recruited to the plasma membrane,
which then recruit clathrin (50). As membrane invagination continues and clathrin
polymerizes, AP2 stabilizes the coated pit. Next, the GTPase dynamin is required to induce
fission of a deep clathrin-coated pit and its cargo from the plasma membrane, resulting in the
formation of an endocytic vesicle (45). By the end of this initial step in the endocytic pathway,
an early endosome is formed which can then be sorted to its destination.
Internalized EGFRs follow an endocytic itinerary in which they pass through early
endosomes and late endosomes/multivesicular bodies (MVB) prior to the lysosome for
degradation. Ubiquitination of the cytoplasmic tail of EGFR allows recognition by the ESCRT
machinery, a group of cytosolic protein complexes required for internalization from the
endosomal membrane into intraluminal vesicles (ILVs), and subsequent degradation upon
MVB-lysosome fusion (Figure 4) (51–58). Mono-ubiquitination of cargo at the plasma
membrane can promote intracellular protein movement through the endocytic pathway, but it
does not necessarily serve as a signal for lysosomal degradation (59).

Conversely,

polyubiquitination of cargo at the membrane of early endosomes is a necessary step for
receptor internalization into ILVs and subsequent degradation by the lysosome. (50, 60).
Regulation of EGFR ubiquitination and degradation can affect the total amount of EGFR that
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resides on the cell surface (46). The endocytic pathway can modulate EGFR-mediated
signaling by affecting the number of receptors on the surface of cells.

1.6 Ubiquitination and EGFR Degradation

Ubiquitination is a key regulator of EGFR degradation (53, 61). EGFR may be
ubiquitinated on lysine residues by the E3 ubiquitin ligase Cbl at the plasma membrane (61)
or by the E3/E4 ubiquitin ligase UBE4B at the endosomal membrane (53). Ubiquitination is a
necessary step for lysosomal sorting in the endocytic pathway (46). A dominant negative of
Cbl (62) or a depletion of UBE4B (53) can lead to a decrease of EGFR lysosomal degradation.
Lysine residues 29, 48, and 63 are targets of mono-ubiquitination by the E3 ligase Cbl (61),
whereas UBE4B can attach ubiquitin at those lysine residues as well as lysine residues 6, 11,
27, and 33 (63). Another key difference between Cbl and UBE4B is that UBE4B can act as
an E4 ligase (63). E4 ligases are capable of ubiquitin chain assembly to mediate
polyubiquitination (64). Furthermore, ubiquitination by UBE4B can be counteracted by the deubiquitinating enzyme USP8 (53). Ubiquitination is an essential step for endosomal sorting
and lysosomal degradation of cargo in the endocytic pathway.
The amount of UBE4B in neuroblastoma cells correlates with patient survival. The
gene for UBE4B resides at the 1p36 chromosome site, which is commonly deleted in one-third
of neuroblastomas (Figure 2) (14, 19, 65). Patients with lower levels of UBE4B have a poor
prognosis compared to patients with normal levels (18), even when stratified by disease stage
(19). Furthermore, it has been suggested that decreased UBE4B levels are a predictor of relapse
in low and intermediate risk pediatric patients (19). Thus, the levels of UBE4B correlate with
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neuroblastoma patient outcomes, and understanding how decreased UBE4B levels contribute
to poor prognosis through the proteins that it regulates may aid in finding new treatment
approaches.
One way in which UBE4B may enhance the growth of neuroblastoma is through its
regulation of EGFR. UBE4B protein levels in neuroblastoma patient biopsies are inversely
proportional to EGFR protein levels (18). As the amount of cellular UBE4B decreases, the
expression of EGFR increases and neuroblastoma cells may become more proliferative and
resistant to conventional chemotherapy due to increased stimulation by pro-growth ligands in
the environment (1). Conversely, cancer cells expressing high protein levels of UBE4B are
less responsive to EGF-stimulated growth and EGFR-targeted anti-proliferative therapy (18).
Transiently depleted UBE4B can produce a two-fold increase in whole cell EGFR in cancer
cells in vitro (53). Therefore, low levels of UBE4B may enhance proliferation and worsen
patient outcomes.
The UBE4B enzyme interacts with cargo proteins, like the epidermal growth factor
receptor (EGFR), at the membrane of early endosomes to ubiquitinate them (53). The number
of ubiquitin residues that are added determines whether modified cargo is degraded by the
lysosome or recycled back to the cell’s surface (52). A decrease in the amount of cellular
UBE4B can lead to decreased EGFR degradation due to decreased ubiquitination. Inactivation
of the catalytic activity of UBE4B, which can lead to a dominant negative phenotype, has a
similar effect of lessening EGFR degradation over time (53). Neuroblastoma cells
overexpressing a catalytically inactive form of UBE4B, UBE4B

, decrease their degradation

P1140A

of EGFR, while neuroblastoma cells overexpressing UBE4B increase the amount of EGFR
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that they degrade (53). Thus, it appears that when UBE4B is depleted or inactivated, an
increased amount of EGFR can result.
Increased EGFR levels as a result of decreased amounts of UBE4B can lead to
increased stimulation by growth factors (18) and increased pro-proliferative downstream
signaling (53). The fact that stimulation by growth factors in vitro can enhance downstream
signaling and cell growth provides some evidence that a portion of increased EGFR resides on
the cellular surface. In cervical adenocarcinoma (HeLa) cells, transient depletion of UBE4B
levels followed by stimulation with EGF leads to a significant rise in signaling in the proproliferative MAPK/ERK signaling pathway (53). Moreover, neuroblastoma cells that
overexpress UBE4B have reduced proliferation in response serum and EGF (18). These data
suggest that the mechanism by which low UBE4B levels result in worse patient outcomes may
involve increased growth factor-stimulated proliferation due to increased EGFR levels.

Figure 4. Graphical depiction of EGFR traveling through the endocytic
pathway
UBE4B interacting with EGFR (blue) at the endosomal membrane during trafficking
in the endocytic pathway. The degree of ubiquitination determines cargo fate of either
lysosomal degradation (Lyso) or plasma membrane recycling. Polyubiquitination of
12

the cytosolic-facing segment of the EGFR causes it to be internalized into
intraluminal vesicles of the MVB/late endosome. Degradation of the receptor then
occurs after fusion with the lysosome.
1.7 Mechanism of Cetuximab as a Treatment for Neuroblastoma

Cetuximab (mAb C225 or Erbitux) is a monoclonal antibody that specifically binds to
the EGF receptor (66). It interacts with the extracellular domain of the receptor blocking the
ligand binding site (67). Binding of Cetuximab to EGFR also stimulates receptor
internalization (68). Like other cargo that travels through the endocytic pathway, the receptor
is ultimately either degraded in the lysosome or recycled (47). Cetuximab binding also induces
antibody-dependent cell-mediated cytotoxicity (69).
The benefit of Cetuximab is derived from blocking EGF binding to the EGFR and the
drug’s effective reduction in growth factor receptors in a rapidly proliferating cancers (66, 70).
The number of growth factor receptors has been shown to correlate with an increased rate of
proliferation and resistance to chemotherapy agents that target cell division (71). Cetuximab
has significant therapeutic benefit in treating colorectal cancer (72, 73) and cancers of the head
and neck (74). In non-small cell lung cancer (NSCLC), Cetuximab is effective in patients with
elevated levels of EGFR, regardless of whether those receptors have mutations (75). To date,
however, Cetuximab has not been an effective treatment in neuroblastoma patients. In a phase
1 clinical trial involving treatment of Cetuximab and irinotecan in pediatric solid tumors
(which included just two neuroblastomas), there was no sustained or complete response in the
neuroblastoma patients to the combination therapy (76). The patients in that trial were not
differentiated by the amount of EGFR in their tumors and the sample size was small. In the
case of non-small lung cancer, the greatest response to Cetuximab was observed when patients
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were strategically selected based on elevated levels of EGFR (77). Given the fact that onethird of neuroblastomas have deletions of the chromosomal location containing the UBE4B
locus (14, 19), it may be possible to strategically select neuroblastoma patients with low levels
of UBE4B for Cetuximab treatment.

1.8 Targeting Signaling Downstream of the EGF Receptor

EGFR transmits signals through activation of many cytosolic signaling cascades,
including Ras/Raf (78), phosphatidylinositol 3-kinase/Akt (79), Jak/STAT (80), phospholipase
C (81), and Nck/PAK signaling pathways (82). Each of these pathways have been implicated
in cell proliferation, and their constitutive activation, independent of EGFR ligand binding, can
blunt the effect of inhibitors that target that receptor (83). Consequently, combination therapies
that target a pathway downstream of EGFR can increase the efficacy of EGFR-targeted therapy
(84). This combination therapy approach has been used successfully in non-small cell lung
cancer using a Jak-2 inhibitor in combination with Cetuximab. In pre-clinical trials, this
combination overcame resistance, synergistically, when compared to Cetuximab treatment
alone (85). Similarly, an increased anti-proliferative effect has been observed in head and neck
squamous cell carcinomas treated with a combination of a Jak-2/STAT3 inhibitor and
Cetuximab (86). It may be possible to simultaneously target EGFR and one member of a
downstream signaling pathway in order to produce an anti-proliferative effect in
neuroblastoma tumor cells.
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1.9 Design of this Study

One of the goals of our research was to understand the role of UBE4B in regulating the
levels of other proteins and mediating the chemotherapy response in neuroblastoma. I created
a model neuroblastoma chemotherapy-resistant cell line where UBE4B was depleted to
undetectable levels. This model was used to test several specific hypotheses:

1. Does stable depletion of UBE4B lead to increased EGFR in neuroblastoma?
2. Does this increase in EGFR make cells more sensitive to EGFR-targeted drug
agents?
3. Does a depletion of UBE4B lead to other protein changes in neuroblastoma?
4. Can proteins that increase in amount due to UBE4B depletion be targeted to
reduce neuroblastoma cell growth in vitro?
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Figure 5. Graphical depiction of UBE4B’s ubiquitination role in EGFR
degradation
UBE4B ubiquitination determines the fate of endosomal cargo like EGFR that is
trafficked through the endocytic pathway. Understanding which proteins are elevated
as a result of a UBE4B depletion may lead to downstream targets for neuroblastoma
patients with 1p36 deletions.

First, I used an in vitro metabolic activity assay to identify neuroblastoma cell lines that
were either resistant or sensitive to conventional chemotherapy agents. I then used two resistant
and sensitive cell lines to determine whether Cetuximab could be combined with the
chemotherapeutic agent irinotecan, a topoisomerase inhibitor, to get a combined antiproliferative effect in vitro, as has been tried in a clinical trial with pediatric solid tumors (76).
Next, I created a model neuroblastoma cell line from the resistant SK-N-AS neuroblastoma
cell line in which UBE4B levels were depleted in a stable fashion using shRNA. These cells
were tested by immunoblot for increased protein levels of EGFR. They were then treated with
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the EGFR-targeted antibody Cetuximab in vitro to study whether growth could be inhibited
after UBE4B protein depletion.
High throughput screening was used to identify changes in amounts of other proteins
as a result of UBE4B depletion. Drug targets for upregulated proteins were then investigated
based on published pre-clinical and clinical data from other cancers. The two proteins selected
for further interrogation were the EGFR and STAT5a, a signal transducing protein involved in
EGFR-mediated signaling. I then used in vitro experiments to study whether the model
neuroblastoma cells depleted of UBE4B became more sensitive to a STAT5 inhibitor by itself
or in combination with the EGFR-inhibiting antibody Cetuximab. In addition, in vitro
experiments to study the effect of these agents on the amount of neuroblastoma cell migration
and apoptosis were performed.
The results reported here show that a model neuroblastoma cell line containing low
levels of UBE4B has elevated amounts of EGFR and STAT5a, which makes it sensitive to
growth inhibition by EGFR- and STAT5-targeted drug agents. This approach for inhibiting
neuroblastoma’s growth may be effective for the one-third of neuroblastoma patients who have
a 1p36 depletion leading to lower levels of UBE4B in their tumors.
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CHAPTER 2 – Materials and Methods

2.1 Tissue Culture

The SK-N-AS, SK-N-BE(2), CHP134, LAN5, CHLA20, and SK-N-SH human
neuroblastoma cell lines used in this study have been previously utilized and described by our
laboratory (87). Cells were cultured in RPMI media (Corning Life Sciences, Tweksbury, MA)
supplemented with 10% fetal bovine serum and 1% L-glutamine. TLA-HEK293T cells used
for lentivirus production (Thermo Fisher Scientific, Waltham, MA) were cultured in DMEM
with 10% fetal bovine serum at 37°C with 5% CO and passaged to maintain 20-80%
2

confluence.

2.2 Chemotherapy Agents

The chemotherapy agents topotecan, irinotecan, doxorubicin, temozolomide, and
cisplatin were obtained from Sigma (St. Louis, MO). Topotecan was dissolved in PBS to make
a 0.5 mM stock, irinotecan was dissolved in DMSO (Sigma) to make a 50 mM stock,
doxorubicin was dissolved in PBS to make a 6.9 mM stock, temozolomide was dissolved in
DMSO to make a 50 mM stock, and cisplatin was dissolved in PBS to make a 3 mM stock.
Cetuximab (Erbitux, Eli Lilly, Indianapolis, IN) with a stock concentration of 2 mg/mL was a
generous gift of the University of Texas MD Anderson Cancer Center pharmacy. The STAT5
inhibitor SH-4-54 (ApexBio Technology, Houston, TX) was purchased as a 10 mM stock
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solution in DMSO. Drug dilutions for experiments were prepared in cell culture media from
these stocks just prior to cell treatment.

2.3 Lentiviral Depletion of UBE4B in Neuroblastoma Cells

UBE4B-shRNA was obtained from Sigma’s Mission shRNA library. See table for
sequences (Table 1). Lentiviral packaging plasmids pMD2.g, pRSV-Rev, and pMDLg/pRRE,
and scrambled shRNA sequences were a gift of Dr. Sara Prijic (UTHealth McGovern Medical
School, Houston, TX). Plasmid DNA was purified (Qiagen, Germantown, MD) and
Lipofectamine 3000 (Thermo Fisher Scientific) was used to transfect HEK 293T cells (60%
confluent at the time of transfection) using the following amounts of DNA in each reaction:
2.24 µg shDNA or shScrambled, 5.6 µg pMDLg/pRRE, 2.8 µg pRSV-Rev, and 3.36 µg
pMD2.g. Twenty four hours following HEK 293T cell transfection, the media was changed to
normal media and cells were incubated for an additional 48 hrs. After 48 hours, supernatant
was collect to obtain virus. Target neuroblastoma cells were plated at 80% confluence and
infected using the viral-rich media that had been mixed with 1 μg polybrene (Sigma) per 1 mL
of media and filtered through a 0.45-micron PVDF membrane (Thermo Fisher Scientific). The
filtered virus was incubated at room temperature for 10 min and transferred onto the target
cells. The target cells were incubated overnight with virus, after which the media was changed
to virus-free media. Two days after infection, the media was supplemented with 1 μg
puromycin per 1 mL of media to select for infected cells. Cells were selected until untreated
control cells completed died, which typically took approximately 4 days. A Western blot was
used to confirm UBE4B levels.
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Sigma ID #

UBE4B shDNA Sequence

TRCN0000338295

CCGGGCCTAGTTGCCGTCGCTATATCTCGAGATA
TAGCGACGGCAACTAGGCTTTTTG

TRCN0000007548

CCGGGCAGGGATCAAATCCACAATACTCGAGT
ATTGTGGATTTGATCCCTGCTTTTT

TRCN0000350907

CCGGGCAGGGATCAAATCCACAATACTCGAGTA
TTGTGGATTTGATCCCTGCTTTTTG

TRCN0000338354

CCGGGAAGTGTTCAAGCAGATATTTCTCGAGAA
ATATCTGCTTGAACACTTCTTTTTG

Table 1. shDNA sequences used for depleting UBE4B in neuroblastoma cell lines.

2.4 Western Protein Blotting

Cell pellets were collected by scraping cells or using 5 mM EDTA (Millipore Sigma,
Billerica, MA) to release them from their culture dishes. Cells were centrifuged at 1500 x g for
10 min, resuspended in a small volume of RIPA (1% Triton X-100, 6.1% SDS, 150 mM NaCl,
50 mM Tris-HCl pH 8.0, 1% NP-40) buffer with a protease inhibitor cocktail (10 mM
leupeptin, 1 µg/µL pepstatin, 0.3 mM aprotinin, and 1.74 µg/µL PMSF), lysed using sonication
(5 pulses of 1 second at output control 3, Branson Sonifier 250, VWR Scientific), and
centrifuged at 2000 x g to separate membranes from cytosolic protein. Lysate was kept on ice
throughout the lysis process. The amount of protein in each sample was quantified (BCA
protein assay, Thermo Fisher, Walham, MA) according to the manufacturer’s instructions.
Samples of lysate (20 μg) were mixed with 6x loading buffer (50 mM Tris-HCl at pH 6.8, 4%
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SDS, 60% glycerol, 0.6% bromophenol blue, and 30% ß-mercaptoethanol), boiled for 5 min
at 100°C, and separated using polyacrylamide gel electrophoresis (SDS-PAGE, 5% stacking,
10% separating). Proteins were transferred to nitrocellulose membranes in a buffer of tris,
glycine, and methanol (100 V and 500 mAmp) for an hour. The resultant membrane was
stained with Ponceau S (Sigma). Next the blot was blocked for an hour at room temperature
with either BSA (1% in PBS) or nonfat dried milk (5% in PBS), depending on the antibody.
The blots were incubated overnight at 4°C with either anti-actin antibody (Sigma, A2066),
anti-UBE4B antibody (Abcam), anti-EGFR antibody (Invitrogen, Carlsbad, CA), or antiSTAT5 antibody (Cell Signaling, Danvers, MA). Membranes were subsequently washed three
times with PBS-T and then incubated in a goat anti-rabbit secondary antibody (1:5000 for
EGFR, 1:2000 for UBE4B, 1:5000 for actin, and 1:2000 for STAT5). Membranes were washed
three times and developed using chemiluminescence (SuperSignal West Pico, Thermo Fischer
Scientific) and visualized using x-ray film.

2.5 MTT (MethylThiazolyldiphenyl-Tetrazolium bromide) Cell Metabolic Activity Assays

Human neuroblastoma cells were diluted 1:1 with trypan blue and counted with the
Countess automated cell counter (Invitrogen, Carlsbad, CA). Cells were then diluted in RPMI
media to enable plating 7.5e3 cells per well on a 96-well plate with a multichannel pipette and
incubated for 24 hours to allow adherence. On the second day, the media from each well was
aspirated and replace with 100 µL of complete RPMI media containing either a chemotherapy
agent or the appropriate vehicle. For experiments where only a 72-hour time point was taken,
the treated cells were incubated for three days at 37°C with 5% CO . In experiments involving
2
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Cetuximab, the drug was added fresh to the cells daily. For experiments involving daily
measurements, cells were plated in three sets so that daily MTT assays could be performed.
MTT measures mitochondrial metabolic activity and is a surrogate measure for cell viability
in response to a drug challenge. A stock solution of 5 mg/mL MTT (Sigma) in PBS was first
prepared and 10 µL of MTT were added to each 100 µL of media (final concentration 0.5
mg/mL). The plate was protected from light and incubated for 4 hours prior to removal of the
media and non-reduced MTT, and 100 µL of DMSO was added to each well, incubated for a
further 10 min, and the absorbance (560 nm) of each well was measured. The background
absorbance of media only with the MTT reagent was measured and subtracted. Samples
assessed at 72 hours only were compared to the absorbance of control-treated cells. Samples
assessed daily were compared to the absorbance of cells at Day 0 before a drug or inhibitor
was added. The significance of drug treatments in depletion cells was assessed with a twoway ANOVA using a Dunnett's multiple comparisons test. All statistical analysis was
performed with GraphPad Prism software version 7 (La Jolla, CA).
For the IC growth inhibition experiments in Figure 6, we first assessed the literature
50

for a published IC values for our model neuroblastoma cell lines and chemotherapy agents.
50

We examined the concentrations of selected chemotherapeutics required to inhibit the
proliferation of various neuroblastoma cell lines. Calculation of IC values was done using a
50

Boltzmann best fit regression. Only data with a Pearson correlation coefficient > 0.8 and at
least three cell viability measurements between 20% and 80% were used for analysis.
Significance of the IC results was assessed with a one-way ANOVA with a Tukey multiple
50

comparison test.
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2.6 Cleaved Caspase Assay

Wild type, scrambled, and shUBE4B SK-N-AS cells were counted with the Countess
automated cell counter and then plated at a density of 4e5 cells in 96-well plates and allowed
to adhere overnight. On the second day, the media was aspirated from these cells and replaced
with 100 µL of media alone, media with 5 μM SH-4-54, media with 2 μM Cetuximab, or media
containing a combination of 5 μM SH-4-54 and 2 μM Cetuximab. CellEvent Caspase 3/7
Green Detection Reagent (Invitrogen, Carlsbad, CA) was added to the media of all four
treatment groups at a final concentration of 3 μM, and the cells were incubated for 48 hrs at
37°C with 5% CO protected from light. Next, the cells were imaged using first phase contrast
2

microscopy and then florescent microscopy using a GFP filter. The percentage of greenfluorescing cells to total cells was then calculated. Significance between treatment groups was
determined with a two-way ANOVA with a Dunnett multiple comparison test using GraphPad
Prism.

2.7 Transwell Migration Assay

Cells were seeded in six well plates at a density of 3e5 cells per well and incubated
overnight at 37°C with 5% CO to adhere. On Day 2, the cells were treated vehicle (DMSO and
2

PBS) and media alone, media with 5 μM SH-4-54, media with 2 μM Cetuximab, or media
containing a combination of 5 μM SH-4-54 and 2 μM Cetuximab. The cells were incubated
for an additional 24 hours. On the third day, the cells were separated from the dish with trypsin
and counted using the Countess automated cell counter. Next, EGF was added to RPMI for a
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concentration of 100 ng/mL, and 750 μL was added to wells of a 12 well plate. Falcon Cell
Culture inserts (Corning Life Sciences, Tweksbury, MA) with 8 μM pores were submerged in
the wells. Finally, 1.5e5 of the pre-treated SK-N-AS cells were diluted in serum-free RPMI
media and added to the cell culture insert. The number of cells added was based on the number
of viable cells from the Countess cell counting procedure so that an equal number of living
cells was added to each insert. The cells were allowed to incubate overnight 37°C with 5%
CO .
2

The following day the cells were washed and fixed for microscopy. First, the noninvading cells were scrubbed from the top surface of the membrane using a cotton-tipped swab
moistened with media for the first scrub and PBS for the second scrub. Next, the membranes
were fixed with 100% methanol for 5 min. The membranes were then rinsed in water for 1 min
and stained with a 1 μg/mL DAPI in PBS with 0.1% Tween for 20 min at room temperature
protected from light. The membranes were then washed again in water for 1 min and inverted
to dry in room air. Lastly, a fine-tipped scalpel was used to cut the membranes from the insert.
The membranes were place bottom-side-up on a glass microscope slide. FluroSave reagent
(Millipore Sigma, Billerica, MA) was added dropwise to the membranes. They were then
covered with glass coverslips and then sealed with nail polish.
The glass slides were protected from light in the fridge at 4°C. The membranes were
later imaged with 10x magnification on a fluorescent microscope. The instrument was set for
DAPI with an excitation wavelength of 358 nm and an emission wavelength of 461 nm. Four
10x fields on each membrane were counted, and then the average was taken per condition to
compute the number of cells per high powered field (HPF). The experiment was performed in
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triplicate and significance was determined with a two-way ANOVA with a Dunnett multiple
comparison test using GraphPad Prism.
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CHAPTER 3 – Characterization of Antiproliferative Response to Chemotherapy in
Neuroblastoma

3.1 Rationale

We wanted to identify an appropriate model neuroblastoma cell line that would be
resistant to chemotherapy treatment in vitro. This line would become the model for future
experiments where UBE4B was depleted. We studied the growth inhibitory effect of five
conventional chemotherapy agents and Cetuximab, a monoclonal antibody that specifically
targets the EGFR, toward seven neuroblastoma cell lines in vitro. Given the different molecular
profiles of these lines, it was not clear how each would respond to an in vitro chemotherapy
challenge. We wanted to identify lines that were especially resistant or sensitive to
chemotherapy in order to select a resistant line for later experiments. We also wanted to use a
cell line with a 1p deletion and possibly higher levels of EGFR to assess whether Cetuximab
combined with a conventional agent that targets cell division might be able to inhibit
neuroblastoma’s growth.

3.2 SK-N-AS and SK-N-BE(2) are Resistant and LAN5 and CHP134 are Sensitive
Neuroblastoma Cell Lines

The relative sensitivity or resistance of commonly used neuroblastoma cell lines to
chemotherapeutics has been previously described (88), however, cross-lab variability because
of cell passage number, culture conditions, drug formulation variability, and assay variability
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can affect these results (89). Therefore, we first examined the sensitivity of seven
neuroblastoma cell lines (Table 2) to five chemotherapeutics in MTT cell metabolic activity
assays. The IC (concentration of drug that inhibits proliferation by 50%) was calculated for
50

each drug in each cell line. SK-N-AS and SK-N-BE(2) cell lines were the most resistant, and
LAN5 and CHP134 cells lines were the most sensitive to chemotherapeutics (Figure 6). With
the exception of doxorubicin, the IC for SK-N-AS was significantly higher for each
50

chemotherapy drug when compared with many of the other cell lines tested.

Table 2. Molecular characteristics of the neuroblastoma cell lines used in this
study.
All cell lines except SK-N-SH had either a 1p deletion or translocation. The 1p36 site
specifically is the location of UBE4B. Additionally, the lines NGP, CHP-134, LAN5,
and SK-N-BE(2) had N-myc amplifications which are a bad prognostic indicator in
patients. Finally, the lines SK-N-AS, CHLA-20, and SK-N-BE(2) have been
described in the literature as being resistant (R), while CHP-134 has been described
as sensitive (88).
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Figure 6. IC50s of model neuroblastoma cells lines to chemotherapy agents
The inhibitory concentration required for 50% inhibition of proliferation (IC ) in vitro
at 72 hours varies across seven neuroblastoma cell lines using five chemotherapy
agents with varying mechanisms of action. We identified SK-N-AS as being more
resistant because these cells required higher concentrations of chemotherapeutics for
inhibition with all drugs except cisplatin. We identified LAN5 and CHP134 as more
sensitive cell lines because lower drug doses were needs to inhibit proliferation.
Graphs show the average of at least three independent trials + the SD.
50

28

3.3 Cetuximab and Irinotecan Combination Treatment Increases the Efficacy of Low Doses of
Irinotecan

EGFR has been reported to be overexpressed in proliferating neuroblastoma, especially
resistant lines taken from relapsed patients (1). After establishing the resistant and sensitive
cell lines in our panel, we next studied whether Cetuximab, a monoclonal antibody that
specifically targets EGFR, in combination with irinotecan, which interferes with DNA
replication, would inhibit proliferation. Cetuximab has had limited efficacy toward
neuroblastoma in patients (76, 90), but there is sparse in vitro data published to describe the
response of neuroblastomas to the anti-proliferative effect of Cetuximab. EGFR has been
reported to be elevated in resistant neuroblastomas (1, 2), so we examined whether this
combination of Cetuximab and irinotecan would be effective in the resistant lines SK-N-AS
and SK-N-BE(2) when compared with the more sensitive LAN5 and CHP134. The results
showed no significant change in the IC s between irinotecan monotherapy and combination
50

therapy at 72 hours (Figure 7). However, the combination did significantly improve the
efficacy of low doses of irinotecan in all lines except SK-N-BE(2). Cetuximab alone did not
have much of an effect on proliferation and neither did the lowest dose of irinotecan, but the
combination showed a significant change (Figure 8). This suggests that Cetuximab may not be
effective at inhibiting growth of wild type cells, but it can enhance the cytotoxic efficacy of
low concentrations of irinotecan.
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Figure 7. Combined treatment of wild type SK-N-AS can increase the antiproliferative efficacy of low concentrations of irinotecan when measured at 72
hours.
Cetuximab was combined with increasing concentrations of irinotecan to test for
synergy between the two agents in two resistant lines SK-N-AS, SK-N-BE(2) (a, b)
and two sensitive lines LAN5, CHP134 (c, d). Proliferation was assessed at 72 hours
using an MTT assay for mitochondrial activity.

30

Figure 8. Comparison of low dose irinotecan combined with Cetuximab
sensitive and resistant neuroblastoma cell lines
In a post-hoc analysis, the effectiveness of the lowest concentration of irinotecan was
compared with Cetuximab and the combination of both drugs for each cell line (a d) revealing that while the IC did not appreciably change, the efficacy of lower
irinotecan doses did increase when combined with Cetuximab. All graphs represent
the means + standard deviation of at least three independent trials.
50

3.4 Conclusions
These experiments indicate that of all the neuroblastoma cell lines tested, SK-N-AS
and SK-N-BE(2) are two of the most resistant lines to the five chemotherapy agents examined.
This was one reason for selecting SK-N-AS for future experiments of this study as a model
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cell line that is resistant to treatment. In addition, it does not appear that the addition of
Cetuximab, an EGFR inhibitor, significantly changes the IC for irinotecan in the four cell
50

lines that were tested in vitro, although addition of Cetuximab to irinotecan did appear to
enhance the growth inhibitory effect of low doses of irinotecan.
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CHAPTER 4 – Anti-proliferative Effect of EGFR Targeted Therapy

4.1 Rationale
We wanted to study whether a depletion of UBE4B levels in a treatment resistant
neuroblastoma cell line could make them more sensitive to growth inhibition with a drug agent
that targets EGFR. Transient UBE4B depletion (53) results in a two-fold increase in the levels
of EGFR in HeLa cells. Neuroblastoma cells overexpressing UBE4B were less sensitive to
the anti-proliferative effects of Cetuximab (18). Our hypothesis was that stable depletion of
UBE4B levels in a model neuroblastoma cell line would increase EGFR levels. This would
introduce more targets to binding of the EGFR-targeted antibody Cetuximab and make those
cells prone to growth inhibition by Cetuximab.

4.2 Depletion of UBE4B in SK-N-AS Leads to Increased EGFR Levels and Increased AntiProliferative Response to Cetuximab

Since UBE4B promotes the degradation of the EGFR (53), we hypothesized that
resistant neuroblastoma cells depleted of UBE4B might become more sensitive to EGFR
inhibition. UBE4B was depleted in SK-N-AS cells using a lentiviral-delivered shRNA against
UBE4B followed by antibiotic selection. After one week of selection, we observed nearly
undetectable levels of UBE4B in SK-N-AS cells (Figure 9). Since EGFR levels and
downstream MAPK/ERK signaling are regulated by UBE4B (19, 53), we examined EGFR
levels in the UBE4B-depleted SK-N-AS cells and observed a two-fold increase in EGFR levels
(Figure 9), similar to what we have previously observed after acute depletion (53). Increased
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EGFR levels promote cell proliferation in neuroblastoma (2) and lead to poor patient outcomes
(18, 91). We hypothesized that elevated EGFR expression would enable anti-EGFR antibody
(66) therapeutic efficacy. Treatment with increasing concentrations of Cetuximab significantly
inhibited the proliferation of UBE4B-depleted SK-N-AS cells but did not inhibit the
proliferation of parental cells (Figure 10). These data suggest that the elevated EGFR levels
produced by UBE4B depletion may provide additional targets for Cetuximab allowing the drug
to inhibit proliferation.
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Figure 9. Western blot and quantitation of UBE4B depletion and subsequent
change to EGFR in neuroblastoma SK-N-AS with stable UBE4B expression
Depletion of UBE4B to undetectable levels using shRNA in the SK-N-AS
neuroblastoma cell line leads to a two-fold increase in EGFR. Quantifications in are
the averages of three independent trials + the SD.
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Figure 10. Growth inhibitory response to the EGFR-targeted antibody
Cetuximab in neuroblastoma SK-N-AS with stable UBE4B expression
Treatment of model SK-N-AS neuroblastoma cells bearing a stable depletion of
UBE4B (shUBE4B) with 1 𝜇𝑀 and 2 𝜇𝑀 of Cetuximab, a drug specific to EGFR, led
to a significant drop in growth over 72 hours as measured by an MTT assay.
4.3 Conclusions
These experiments demonstrated that it is possible to deplete UBE4B to undetectable
levels using a lentiviral shRNA delivery system resulting in a concurrent two-fold increase in
EGFR protein levels. In vitro MTT assays revealed that Cetuximab (1 and 2 µM) can
significantly inhibit the growth of UBE4B-depleted SK-N-AS cells a decrease not observed in
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parental cells or those transduced with a scrambled shRNA suggesting that the change in
response is a result of UBE4B depletion.
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CHAPTER 5 – Downstream Protein Changes as a Result of UBE4B Depletion
5.1 Rationale
There is an inverse correlation between UBE4B and EGFR levels in neuroblastoma
(18, 19, 53). The increase in EGFR levels that occurs following transient UBE4B depletion
may result from decreased ubiquitination of EGFR resulting in decreased EGFR degradation.
We examined whether other proteins might be increased or decreased in amount as a result of
UBE4B depletion. We stably depleted SK-N-AS cells and assessed lysates using the Reverse
Phase Protein Array (RPPA) method in which the levels of 305 cancer-related proteins were
examined.
5.2 Depletion of UBE4B Leads to a Two-fold Increase in STAT5a

We observed 57 proteins to be increased by two-fold or more (Figure 11a) and 26
proteins decreased by 50% or more (Figure 11b). RPPA analysis confirmed a two-fold increase
in EGFR, consistent with our data (Figure 9) and earlier studies (53). Among the proteins that
were increased in amount, there was a mixture of proteins involved in proliferation and growth
inhibition (Table 3). Among the proteins that were decreased in amount, many were proproliferative in nature (Table 4). We confirmed these increases in STAT5a protein levels using
immunoblotting (Figure 12), and we found that it remained increased two-fold. These data
suggest that EGFR and STAT5a levels increased specifically because of UBE4B protein
depletion in the model SK-N-AS neuroblastoma cell line.
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Figure 11. Reverse Phase Protein Analysis (RPPA) of increased and decreased
proteins subsequent to UBE4B depletion in neuroblastoma SK-N-AS
Reverse phase protein analysis was used to assay 305 proteins increased or decreased
in amount as a result of a UBE4B depletion the neuroblastoma SK-N-AS. This subset
of that data shows proteins that are either increased two-fold or more (a) or decreased
50% or more (b) relative to the wild type and scrambled versions of that cell line.
The red arrows indicate EGFR and STAT5a, the two proteins that were studied here.

40

Protein
14-3-3-𝜁
BiPGRP78
p27-Kip-1
Bid
Bim

PEA-15
Atg3
WIPI1
CD171
CD44
CollagenVI
E-cadherin
NCadherin
Stat5a
Box

4E-BP1
EMA
TWIST

Description
Promotes cell proliferation, adhesion and survival,
and it inhibits apoptosis in multiple cancers. (92)
Endoplasmic reticulum chaperone protein necessary
for cancer survival (93)
Negative regulator of apoptosis; not regulated by
MYCN in neuroblastoma (94)
Promotes apoptosis and can be used for survival
prediction in colon cancer (95)
Induces apoptosis and anoikis (96)

Positive regulation of apoptosis (97)
E2-like enzyme that is essential for promoting
autophagy. It is degraded in the presence of
chemotherapy agents like etoposide (98)
Also known as ATG18 and it promotes autophagy
(99)
Cell adhesion marker that has characteristic
expression in many cancers (100)
Mediates cell-cell and cell-matrix adhesion and is
expressed in tumors that are epithelial in origin. It
can be used as a prognostic marker. (101)
Cell adhesion protein that is highly expressed in a
number of cancers (102)
Calcium-dependent adhesion molecule. Its
dysregulation leads to tumor progression (103)
Calcium-dependent adhesion molecule that is
elevated in amounts in tumor tissues (104)
Signal transduction and activation of transcription
(STAT) is activated by EGFR. (105)
Subunit of an E3 ubiquitin ligase. Its dysregulation
leads to human malignancy. (106)
Mediates the regulation of protein translation by
hormones, growth factors, and other stimuli that
signal through the MAPK and AKT pathways. Loss
of 4E-BP1 function induces epithelial-mesenchymal
transition (EMT) and increases metastatic capability
of cancer cells by translational activation of Snail.
(107)
Epithelial membrane antigen is a glycoprotein and
its altered distribution in cells in a prognostic marker
in breast cancer. (108)
Transcriptional regulator of cell migration (109)

Pathway

Function
Antiapoptosis
Antiapoptosis
Antiapoptosis
Apoptosis
Apoptosis

AKT/PKB,
blocks 𝛽catenin

Apoptosis
Autophagy
Autophagy
Cell adhesion
Cell adhesion
Cell adhesion
Cell adhesion
Cell adhesion

Jak/STAT

Cell signaling

JNK

E3 ligase

AKT and
MAPK/ERK

Metastasis
Metastasis
Migration
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NDRG1
_pT346
YB1_pS10
2
CD29

Hes1
MMP2
VHLEPPK1
Vimentin
Cox-IV
Cyclophili
n-F

Stress-responsive protein involved in hormone
responses, cell growth, and differentiation (110)
Y-Box protein 1 mediates pre-mRNA alternative
splicing regulation. It is a promoter of proliferation
(111)
Integrin protein that is marker of metastasis in breast
cancer (112)
Transcriptional repressor that is involved in cell
migration by promoting epithelial mesenchymal
transition (EMT). It mediates crosstalk between
Jak/STAT and Notch signaling through Stat3. (113)
Matrix metalloproteinase-2 promotes cell
migration(114)
Epiplakin 1 (EPPK1) is a cytoskeletal linker protein
that connects to intermediate filaments and controls
their reorganization in response to stress (115)
Intermediate filament that is overexpressed in
epithelial cancers (116)
Cytochrome oxidase that has elevated levels in
colorectal cancer (117)
Accelerates folding of proteins and counteracts p53
regulation of cancer growth (118)

Migration
inhibitor

Proliferation
Pro-migration

Jak/STAT,
Notch

Pro-migration
Pro-migration

Pro-migration
SMAD

Pro-migration
Proliferation
Proliferation

AKT/PI3K,
Growth factor receptor that is increased in amount in MAPK/ERK,
EGFR
many cancers (119)
Jak/STAT
Proliferation
The H3 variant of histones, which are involved in
transcription regulation, DNA repair, DNA
replication and chromosomal stability, has been
shown to common in malignant pediatric brain
Histone-H3 cancers. (120)
Proliferation

IGFBP2
MIF

MSI2
PI3Kp110-a
PRAS40_p
T246

IGF binding protein 2 inhibition has been shown to
limit tumor proliferation. It potentiates EGFRSTAT3 signaling. (121),(122)
Macrophage migration inhibitory factor is
implicated in the tumorigenesis, angiogenesis, and
metastasis of many cancer phenotypes (123)
RNA binding protein that promotes TGF-𝛽
signaling and non-squamous cell lung cancer
metastasis (124)
This is a specific mutation in Phosphoinositide-3kinase (PI3K) signaling.
Proline-rich AKT substrate and subunit of
mTORC1, which regulates cell growth and survival
in response to nutrient and hormonal signals. (125)

STAT

Proliferation

MAPK/ERK,
AKT/PI3K
Proliferation
TGF- 𝛽

Proliferation

PI3K/AKT

Proliferation

PI3K/AKT

Proliferation
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TFAM

Stathmin-1

Binds to the mitochondrial light strand promoter and
functions in mitochondrial transcription regulation.
Its knockdown lessens proliferation (109)
Microtubule destabilizer that plays an important role
in cell cycle progression, segregation of
chromosomes, clonogenicity, cell motility and
survival. Its overexpression has been reported in
malignant hematopoietic cells. (126)

Negative regulator of apoptosis and that increases
breast cancer cell invasion. (127)
Highly expressed in many cancers. It converts
prostaglandin H2 to make PGE2 and promotes
Cox2
proliferation and apoptosis (128)
Receptor tyrosine kinase which mediates the
IGFRb
pleiotropic actions of insulin (129)
Insulin
Insulin receptor 𝛽 signaling may be highly
receptor
stimulated and therefore targeted in certain cancers.
𝛽signaling (130)
Nuclear transcription factor that mediates response
to growth factors. It is involved in tumor initiation,
Creb
progression and metastasis. (131)
Coordinates activity of deubiquitinating enzymes
ENY2
and its dysregulation can promote cancer (132)
Part of the BRCA-1 complex. Its activation through
MERIT40_ phosphorylation mediates DNA repair after cancer
pS29
treatment with doxorubicin. (133)
Blocks the nuclear translocation of the
phosphorylated form (by AKT1) of SRPK2. It is a
tumor suppressor. (134)
14-3-3-𝛽
Involved in cell cycle checkpoint and DNA repair
activities. It is a known tumor suppressor in breast
53BP1
cancer. (135)
Negative regulator of proliferation and acts as a
p16INK4a tumor suppressor (136)
Inhibits translation initiation and cap-dependent
translation and functions as a tumor suppressor
Pdcd4
(137)
Tumor suppressor that may be inactivated in many
Smad4
cancers (138)
The superoxide dismutase 2 destroys superoxide
radicals. Polymorphisms may increase cancer risk.
SOD2
(139)
DJ1

TAZ

Restricts proliferation and promotes apoptosis (140)

Proliferation

AKT/PKB

Proliferation
Proliferation
and antiapoptosis

MAPK, PKB

Proliferation
and apoptosis
Proliferative
receptor

MAPK/ERK, Proliferative
AKT/PI3K
receptor
AKT/PKB

AKT

Protooncogene
Protooncogene
Resistance
mediator

MAPK/ERK, Tumor
Hippo
suppressor
Tumor
suppressor
Tumor
suppressor

TGF-𝛽

Tumor
suppressor
Tumor
suppressor

Hippo &
Wnt

tumor
suppressor
Tumor
suppressor
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UBAC1
YAP_pS12
7

Caveolin-1
eIF4E
eIF4E_
pS209

PAI-1

PKC-𝛿
_pS664

E3 ligase that causes proteasome-mediated
degradation of NF-κB. It is also known as KPC1.
(141)
Restricts proliferation and promotes apoptosis. It
overlaps with TAZ (140)
May act as a scaffolding protein within caveolar
membranes and is associated with tumor
progression. Depletion leads to altered Jak/STAT,
JNK, and Src signaling. (142)
Translation initiation factor. Its phosphorylation
promotes tumorigenesis. (143)
Phosphorylation site for eIF4E (143)
Plasminogen activator inhibitor 1 is a negative
regulator of cell adhesion. It has a pro-tumorigenic
role in cancer by promoting angiogenesis and tumor
cell survival. (144)
Calcium-independent, phospholipid- and
diacylglycerol (DAG)-dependent serine/threonineprotein kinase. This mutation promotes
tumorigenesis in pancreatic cancer. (145)

E3 ligase
Hippo &
Wnt
Jak/STAT,
JNK, Src
MAPK and
AKT/PI3K
MAPK and
AKT/PI3K

Tumor
suppressor
Tumor
suppressor

Tumorigenic
Tumorigenic
Tumorigenic

Tumorigenic

PKC

Tumorigenic
(when
mutated)

Table 3. Description of proteins increased two-fold or more subsequent to
UBE4B depletion in neuroblastoma SK-N-AS
The proteins that were elevated two-fold or more in the RPPA analysis of SK-N-AS
cells depleted of UBE4B were analyzed to determine their role in the cell and
associations with known signaling pathways.
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Protein

AMPK𝛼

Cyclin-B1
PLK1

DUSP4

Raptor
mTOR

PKCa
BAP1

ADAR1

Rictor
TRIM25

Description
Catalytic subunit of AMP-activated protein
kinase (AMPK). Regulates cellular metabolism
and is associated with cell growth, metabolism,
and autophagy. Downregulation in gastric
cancer is associated with poor prognosis. (146)
Essential for the control of the cell cycle at the
G2/M (mitosis) transition. High levels are
associated with poor prognosis in breast cancer.
(147)
Serine/threonine-protein kinase and positive
regulation of ubiquitin protein ligase activity.
(148)
Regulates mitogenic signal transduction by
dephosphorylating both threonine and tyrosine
residues on the MAP kinases ERK1 and ERK2.
(149)
Regulates mTORC1 activity. Upregulation
makes cells less sensitive to PI3K/AKT
pathway inhibition (150).
Serine/threonine protein kinase which is a
central regulator of cellular metabolism, growth
and survival (151).
Calcium-activated, phospholipid- and
diacylglycerol (DAG)-dependent
serine/threonine-protein kinase important in cell
signaling. (152)
Specifically mediates deubiquitation of histone
H2A and regulates cell growth. (153)
Catalyzes the hydrolytic deamination of
adenosine to inosine in double-stranded RNA
(dsRNA). This is referred to as A-to-I RNA
editing. It is associated with tumor-infiltrative
lymphocytes in triple negative breast cancer.
(154)
Subunit of mTORC2 that functions upstream of
Rho GTPases to enhance cell migration.
Overexpression yields poor prognosis in colon
cancer. (155)
E3 ubiquitin ligase that enhances cell growth
and proliferation in cancer by modulating p53
signaling. (156)

Pathway

Function

AMPK

Autophagy

Cell cycle
regulator
Cell division
regulator

MAPK/ERK

Cell signaling

PI3K/AKT

Cell signaling

PI3K/AKT

Cell signaling

PKC

Cell signaling,
pro-proliferation
Deubiquitation
and tumor
suppressor

Pro-migration

PI3K/AKT

Pro-migration
Pro-proliferation;
E3 ubiquitin
ligase
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A-Raf

eIF4G
S6

Src_pY527

Stat3

TFRC

FAK_pY397
𝛽-Catenin
eEF2
PTEN

TSC1

Tuberin
TSC2

Isoform of Raf which is involved in cancer
proliferation, migration, and invasion through
involvement in the MAPK pathway. (157)
Commonly found in breast cancer and increases
translation for proteins required for
proliferation and survival (158)
Ribosomal protein that regulates cell growth
and proliferation. Reduced phosphorylation can
increase sensitivity to MEK inhibition. (159)
Non-receptor protein tyrosine kinase that is
involved in the regulation of cell growth and
survival, apoptosis, cell-cell adhesion,
cytoskeleton remodeling, and differentiation.
Overexpressed in a number of human cancers.
(160)
Signal transducer and transcription activator
that mediates cellular responses to interleukins,
KITLG/SCF, LEP and other growth factors.
(161)
Cellular uptake of iron occurs via receptormediated endocytosis of this ligand-occupied
transferrin receptor into specialized endosomes.
Promotes proliferation when overexpressed.
(162)
Non-receptor protein-tyrosine kinase that plays
an essential role in regulating cell migration,
adhesion, spreading, reorganization of the actin
cytoskeleton, formation and disassembly of
focal adhesions and cell protrusions, cell cycle
progression, cell proliferation and apoptosis.
(163)
Key downstream component of the canonical
Wnt signaling pathway. (164)
Tumor-associated antigen that is overexpressed
in many types of cancer. (165)
Tumor suppressor (166)
TSC2, inhibits the nutrient-mediated or growth
factor-stimulated phosphorylation of S6K1 and
EIF4EBP1 by negatively regulating mTORC1
signaling. (167)
In complex with TSC1, this tumor suppressor
inhibits the nutrient-mediated or growth factorstimulated phosphorylation of S6K1 and
EIF4EBP1 by negatively regulating mTORC1
signaling. (167)

MAPK/ERK

Pro-proliferation

Pro-proliferation
PI3K/AKT

Pro-proliferation

Pro-proliferation

Pro-proliferation

Pro-proliferation

Pro-proliferation
and migration
WNT

Proto-oncogene

PI3K/AKT

Tumor antigen
Tumor
suppressor

PI3K/AKT

Tumor
suppressor

PI3K/AKT

Tumor
suppressor
46

FASN

Fatty acid synthetase whose overexpression is
common in many types of cancer. (168)

Tumor marker

Table 4. Description of proteins decreased 50% or more subsequent to UBE4B
depletion in neuroblastoma SK-N-AS
The proteins that were decreased by 50% or more in the RPPA analysis for SK-N-AS
cells depleted of UBE4B were analyzed to determine their role in the cell and
associations with known signaling pathways.

Figure 12. Western blot and quantitation of changes in STAT5 in
neuroblastoma SK-N-AS with UBE4B depletion
One protein of interest, STAT5a, increased two-fold in the RPPA dataset and this
increase was then confirmed with quantitative Western immunoblotting.
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5.3 Conclusions
I observed that depletion of UBE4B protein in SK-N-AS cells results in increases and
decreases in the levels of a number of proteins. EGFR and STAT5a levels both increased twofold.

These data suggest that that these two pro-proliferative proteins can be targeted

individually or in combination in order to inhibit the growth of the model neuroblastoma cells
in vitro.

48

CHAPTER 6 – Growth Inhibitory Effect of Combined EGFR and STAT5 Targeted
Therapy

6.1 Rationale

We wanted to test whether targeting EGFR and STAT5a pharmacologically could
inhibit growth of the model SK-N-AS neuroblastoma cell line depleted of UBE4B in vitro.
The levels of both of these proteins were increased two-fold in the RPPA analysis and
immunoblot of cell lysates. We also found evidence in the literature of studies that had targeted
either EGFR (18, 91) or STAT5 (169) in neuroblastoma. Our hypothesis was that dual
inhibition of both EGFR and STAT5 would reduce growth in vitro and increase apoptotic cell
death. Dual inhibition might also prevent migration in vitro, which is an early step in metastasis
(170).

6.2 Depletion of UBE4B Enhances the Anti-Proliferative and Pro-Apoptotic Effect of
Cetuximab and the STAT5 inhibitor SH-4-54

STAT5a is a member of the Jak/STAT signaling pathway that can be activated by
EGFR (171). STAT5a levels are increased in proliferative cancers, and its constitutive
activation can contribute to resistance to EGFR-targeted therapies (83). STAT5a has also been
targeted with chemotherapeutics as either monotherapy or combination therapy in other
cancers like leukemia (84, 172) and prostate cancer (173). STAT5 is a part of Jak/STAT
signaling of EGFR (80), and directly inhibiting signaling pathways of EGFR can partially

49

prevent signal transduction even when the EGF ligand is bound (174). Therefore, it may be
beneficial to specifically target both EGFR and STAT5a to reduce cell proliferation and
resistance to targeted therapies. We hypothesized that simultaneous inhibition of EGFR and
STAT5a might be more effective at inhibiting SK-N-AS proliferation than either agent alone.
The rationale for this was that in some cases signaling would be blocked by competitive
inhibition of EGF binding because of Cetuximab, whereas in other cases the ligand would still
bind, but signaling would still be partially inhibited by STAT5 inhibition.
The combination of a STAT5a inhibitor SH-4-54 (5 𝜇M) with Cetuximab (2 µM) has
a significant anti-proliferative effect in UBE4B-depleted SK-N-AS neuroblastoma cells
(Figure 13). This antiproliferative effect was not observed in control cells transfected with a
scrambled shRNA or in parental cells. These data suggest that combined inhibition of EGFR
and STAT5a inhibits SK-N-AS cell growth because of the depletion of UBE4B. We saw signs
of cell detachment and morphology changes in vitro with microscopy when measuring cell
growth (data not shown). Additionally, the fraction of metabolically viable cells began to
decrease at 72 hours as measured by MTT assays. These facts suggest that combined
EGFR/STAT5 inhibition may be producing apoptosis. Moreover, the addition of SH-5-54
appears to potentiate the effect of Cetuximab (Figure 14). The anti-proliferative effect observed
with 2 µM Cetuximab is enhanced by the addition of SH-5-54.

50

Figure 13. Anti-proliferative effect of combination EGFR and STAT5
inhibition in neuroblastoma SK-N-AS with UBE4B depletion.
The proliferation of wild type, scrambled, and UBE4B-depleted SK-N-AS
neuroblastoma cells was measured in the presence of erlotinib, an EGFR tyrosine
kinase inhibitor (c), Cetuximab (a), the STAT5 inhibitor SH-4-54 (f), and a
combination of either the STAT5 inhibitor with erlotinib (d) or STAT5 inhibitor with
Cetuximab (b) using an MTT mitochondrial activity assay for 72 hours.
Measurements were taken daily and normalized to day zero, the time when the drugs
were initially added to cells in vitro. Data points for each graph represent the mean +
the SD from three independent trials.
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Figure 14. Demonstration of potentiation between Cetuximab alone and
Cetuximab with a STAT5 inhibitor in inhibiting the proliferation of
neuroblastoma
The combination of 2 µM Cetuximab with 5 µM of SH-4-54, a STAT5 inhibitor,
shows a potentiation effect (175). Cetuximab alone causes a significant decrease in
proliferation in model SK-N-AS cells with a stable depletion of UBE4B. STAT5
inhibition alone does not show a significant anti-proliferative effect. The combination
of the STAT5 inhibitor SH-4-54 and Cetuximab is greater for all neuroblastoma SKN-AS lines that we tested. In the model SK-N-AS line with a stable depletion of
UBE4B (shUBE4B), there is a significantly greater anti-proliferative effect than in
the wild type or control cells.
We next examined whether the combination of Cetuximab and SH-4-54 affected
apoptosis in UBE4B-depleted cells. UBE4B-depleted SK-N-AS cells, parental cells, or cells
transfected with a scrambled shRNA were treated with Cetuximab and SH-4-54 alone or in
combination. We measured the number of cells that were fluorescently labeled indicating
caspase 3 and 7 activation and calculated the ratio of fluorescently-labeled cells to the total
number of cells (Figure 15). There was an increase from about 1.5% GFP+ cells (cells treated
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with vehicle alone) to 5% GFP+ cells (scrambled cells) or 7.5% GFP+ in wild type SK-N-AS
when they were treated with a combination of Cetuximab and SH-4-54. The model SK-N-AS
depleted of UBE4B increased significantly from 2.5% GFP+ cells with vehicle treatment to
nearly 13% with combination treatment. Treatment with SH-4-54 and Cetuximab alone
showed 4.7% and 5.1% increases, respectively, in cleaved caspases indicating that these agents
have some toxic effect by themselves. These data suggest that the addition of SH-4-54
potentiates the antiproliferative effect of Cetuximab in neuroblastoma SK-N-AS cells, causing
greater cell death than either agent alone.
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Z
Figure 15. Pro-apoptotic effect of combination EGFR and STAT5 inhibition in
neuroblastoma SK-N-AS with UBE4B Depletion
Cetuximab combined with STAT5 inhibition causes apoptotic cell death at 48 hours,
particularly in cells depleted of UBE4B. Wild type SK-N-AS neuroblastoma cells or
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SK-N-AS cells with stable expression of a resistance plasmid with a scrambled insert
or an shUBE4B insert were treated with 5 𝜇𝑀 STAT5 inhibitor, 2 𝜇𝑀of Cetuximab,
or a combination of the two. (a) Caspase-3/7 activity was assessed with the CellEvent
green detection reagent and phase contrast microscopy was used to quantify cell
number. (b) The ratio of green-expressing cells to total number of cells was
significantly greater in UBE4B depleted cells co-treated with the STAT inhibitor and
Cetuximab.

6.3 Combination Treatment with Cetuximab and the STAT5 Inhibitor SH-4-54 Inhibits Cell
Migration In Vitro

One of the challenges in treating stage 4 neuroblastoma is that the disease has often
metastasized prior to diagnosis (7). Cell migration is an initial step in the metastatic process
(170), that can be assessed in vitro. We have shown that the combination of EGFR and STAT5a
inhibition reduces growth and increases apoptosis. Since EGFR activation can underlie
migration (176), we used a transwell migration model to assess whether EGFR and STAT5a
inhibition might affect tumor cell migration.
UBE4B-depleted SK-N-AS cells and control cells (parental cells and those transfected
with a scrambled shRNA) were pre-treated for 24 hours with a combination of Cetuximab (2
µM) and SH-4-54 (5 µM). We observed that Cetuximab and SH-4-54 slightly decreased
migration for parental, scrambled, and UBE4B-depleted cells (Figure 16). However, the
combination of Cetuximab and SH-4-54 significantly reduced transwell migration in UBE4Bdepleted SK-N-AS cells when compared to the effect of the combination in parental and
scrambled control cells (Figure 16). The effect of the combined inhibitors in the depletion line
was also significantly less compared to either STAT5 or EGFR inhibition alone. These data
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suggest that in neuroblastoma cells with low levels of UBE4B, the combination of EGFR and
STAT5 inhibitors may reduce tumor cell migration.

Figure 16. Anti-migratory effect of combination EGFR and STAT5 inhibition
in neuroblastoma SK-N-AS with UBE4B Depletion
Migration of UBE4B-depleted SK-N-AS neuroblastoma cells is impaired when
treated with a combination of the STAT5 inhibitor SH-4-54 and the EGFR inhibitor
Cetuximab. Cells were pretreated with 24 hours with PBS/DMSO vehicle, the
STAT5 inhibitor, Cetuximab, or a drug combination mixed in complete media. Cells
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were then counted and an equal amount of 1.5e5 viable cells was added to the top
surface of transwell membranes. Cells were allowed to grow and migrate for 24
additional hours in the presence of drug at 37°C. Membranes were then washed,
fixed, and stained with DAPI to visualize migratory cells (a) which were then
quantified by counting cells visible in a high-power field at 10x magnification and
averaging at least three fields per condition. The quantitation (b) represents the
average of three trials + the SD.

6.4 Conclusions
We observed that EGFR and STAT5a inhibitors can produce growth inhibitory effects
over a three-day time course in UBE4B-depleted SK-N-AS cells. Growth inhibition was
observed with Cetuximab, but not erlotinib, a tyrosine kinase inhibitor. Addition of a STAT5
inhibitor potentiated the growth inhibitory effect of Cetuximab. In fact, in vitro experiments
suggest that the combination of EGFR and STAT5 inhibitors increased apoptotic cell death of
all cell lines, and impaired cellular migration. The inhibition of migration is greater in the
UBE4B-depleted SK-N-AS cells than in parental cells or those transduced with a scrambled
shRNA. A potential limitation of the cell migration assay was that measurements for migration
were not blinded, which could have introduced bias. It would be ideal to re-score the saved
DAPI-stained transwell membranes from the cell migration experiments using a blinded
observer. This would provide additional validity to these results that suggest an anti-migratory
effect of EGFR and STAT5 inhibition that is greater when UBE4B is depleted. Regardless,
these data suggest that combined inhibition of EGFR and one of its downstream signaling
partners, STAT5, may have a greater inhibitory effect on growth and cell migration in cells
with low levels of UBE4B.
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CHAPTER 7 – Discussion and Future Directions

7.1 Overview

High-risk neuroblastoma is associated with frequent relapses and tumors that are
resistant to treatment (177) and children with refractory or recurrent neuroblastoma have very
poor survival rates (4, 178, 179). We have previously observed that low UBE4B expression is
associated with poor outcomes in patients with neuroblastoma (18). UBE4B is required for
efficient degradation of the EGFR, and UBE4B protein levels are inversely related to EGFR
protein levels (18), signaling (53), and cellular differentiation (19) in patient tumor samples.
We screened a chemoresistant neuroblastoma cell line for intracellular proteins whose levels
are altered when UBE4B is depleted. Interestingly, STAT5a was among the proteins whose
levels were increased and it is also linked to EGFR-mediated proliferative signaling. We found
that in contrast to inhibiting EGFR and STAT5 individually, targeting both EGFR and STAT5
potentiated the inhibition of cell proliferation and migration, and promoted apoptosis in
UBE4B-depleted SK-N-AS cells. These data suggest that multiplexed targeting of EGFR
signaling may be an effective strategy for inhibition of growth when tumors have low levels
of UBE4B. This may not be an effective approach, however, for patients with normal levels of
UBE4B. Instead it should be viewed as a form of personalized cancer therapy for a particular
patient subset: patients whose tumors express low amounts of UBE4B.
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7.2 SK-N-AS as a Resistant Model Cell Line

The cell line SK-N-AS was determined to be more resistant to many of the conventional
chemotherapy agents that we tested. SK-N-AS has been reported to be a resistant cell line (88)
and it was originally cultured from a patient with metastasis to the bone (180). Like most of
the cell lines that we tested (Table 2), it also has a deletion of the 1p chromosome site, which
is the location of UBE4B (65). Low UBE4B protein levels correlate with poor prognosis (18,
19), and this is consistent with the resistant behavior of that neuroblastoma cell line in our
study.
The parental SK-N-AS line we used had detectable levels of UBE4B. Neuroblastoma
is a very heterogeneous cancer (181) with variable expression of UBE4B throughout a single
tumor (19). This heterogeneity is also another contributor to the variable chemotherapy
response in neuroblastoma (181). After depletion of UBE4B, the doubling of EGFR protein
levels seen here was consistent with earlier in vitro experiments in HeLa cervical
adenocarcinoma cells using silencing RNA toward UBE4B (53). This supports the model
suggesting that UBE4B ubiquitinates the EGFR at the endosomal membrane and promotes
receptor degradation (53).

7.3 Cetuximab Enhances the Growth Inhibition of Low Doses of Irinotecan In Vitro

We thought that a combination of irinotecan, a topoisomerase inhibitor, with the antiEGFR antibody Cetuximab might lower the IC necessary for irinotecan to inhibit SK-N-AS
50

proliferation. SK-N-AS cells were more resistant to irinotecan than any other cell line we
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examined, and upregulation of EGFR-mediated signaling has been shown to mediate
irinotecan resistance (182). Additionally, in clinical literature, the combination of irinotecan
and Cetuximab is specifically indicated for colorectal cancer that has become refractory to
irinotecan (183). However, I observed that the IC achieved with irinotecan alone did not
50

change significantly with the addition of Cetuximab. This lack of effect parallels a phase I
clinical trial where irinotecan and Cetuximab were used in combination in pediatric solid
tumors with no therapeutic benefit (76). This might be explained in part by the high cellular
heterogeneity in neuroblastoma (181) leading to inconsistent response to treatments that are
effective in other cancers.
One observation of note with the irinotecan and Cetuximab combination data, was that
the anti-proliferative effect of the lowest doses of irinotecan did seem to be enhanced by the
addition of Cetuximab. This may be because the inhibition of proliferative signaling pathways
caused by EGFR binding by Cetuximab (66) is sufficient to amplify the effects of an agent like
irinotecan which interferes with DNA replication. Clinically, this combination might be used
to enhance the efficacy of smaller doses of irinotecan to limit the toxicities caused by this drug
in children (184).

7.4 UBE4B Depletion Increase Levels of Signaling Proteins (EGFR and STAT5a)

Our study identified many proteins that are increased or decreased in amount following
UBE4B depletion in neuroblastoma cells. Many of the upregulated proteins like SMAD4 (138)
and PEA-15 (185), a tumor suppressor and a positive regulator of apoptosis respectively, are
consistent with a cell inhibiting proliferation. However, other upregulated proteins like EGFR
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and Signal Transducer and Activator of Transcription 5a (STAT5) are consistent with a
hyperproliferative state (186). A thorough review of the roles, pathways, and functions of
proteins that increased or decreased in amount are provided in Table 3 and Table 4 in Chapter
5. Of the proteins increased in amount that were identified for the model SK-N-AS cells
depleted of UBE4B, there were several proteins associated with EGFR signal transduction
pathways like MAP kinase/ERK, Akt/PI3K, and Jak/STAT (187). We subsequently looked
for ways to co-target EGFR and one of its downstream signaling pathways pharmacologically
to test the hypothesis that a combination of agents that would inhibit multiple aspects of EGFR
signaling might provide enhanced antiproliferative responses.
EGFR and STAT5a both increased two-fold in UBE4B-depleted SK-N-AS cells. The
regulation of EGFR trafficking by UBE4B has been described (53). The ubiquitination of
STAT5a is a requisite step for its degradation, but the identity of that E3 ligase has not yet
been established (188). One possibility for the link between STAT5a and UBE4B is that
UBE4B ubiquitinates STAT5a to promote its degradation. Alternatively, UBE4B may lead to
the ubiquitination and degradation of another protein which is a regulator of STAT5a. In either
case, a decrease in UBE4B levels would lead to an increase in STAT5a levels. There was one
other E3 ligase that was downregulated in our RPPA analysis, TRIM25, but we found no
evidence of a demonstrated link between UBE4B and TRIM25, or between TRIM25 and
STAT5a. Therefore, there is reason to believe that reduced ubiquitination of STAT5a might
explain why it increased here, but the exact mechanism will require future investigation.
STAT5 is a member of the Jak/STAT signaling and it has been targeted with specific
drugs as treatments for breast cancer (186), prostate cancer (173), and leukemia (189). STAT5
levels are increased in proliferating tumors (190), and the Jak/STAT pathway is one of the
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signaling cascades that may be activated by EGFR (171). Constitutive activation of STAT5
can contribute to resistance to EGFR-targeted therapies (83). There are also parallel examples
of Jak/STAT inhibition combined with EGFR-targeted therapy in lung (85) and skin
malignancies (174) to successfully inhibit cell growth. This led us to ask whether
chemotherapeutic targeting of both EGFR and STAT5 could significantly decrease
proliferation in model cells with a stable depletion of UBE4B.
There are seven proteins in the STAT family, including STAT1, STAT2, STAT3,
STAT4, STAT5a, and STAT5b (171). The proteins STAT3, STAT5a, and STAT5b are
thought to have a role specifically in the development of cancer, while STAT1 has an opposite
effect (190), and all transmit EGFR signals through the Jak/STAT pathway (191, 192). This
signaling enhances proliferation, cell migration, and angiogenesis (193). STAT5a and STAT5b
are highly similar isoforms of STAT5 that share 93% sequence homology (194, 195). Our
RPPA data for the neuroblastoma SK-N-AS cell line depleted of UBE4B showed that there
was a two-fold increase in STAT5 protein levels, and a 90% decrease in STAT3. In addition,
phosphorylated STAT3 decreased by 56% when compared with parental and scrambled control
lysates. STAT3 and STAT5 are good targets for inhibition to inhibit cancer’s growth (105),
especially in hematologic malignancies (196). However, because of the large overlap between
STAT3 and STAT5 in signal transmission, STAT5 inhibition may not be sufficient to decrease
proliferation if STAT3 protein levels are high (171). In the case of our model SK-N-AS cell
line, the lower levels of STAT3 and activated, phosphorylated STAT3 increase the opportunity
for a STAT5 inhibitor to reduce neuroblastoma’s growth in vitro.
Our data suggest that inhibition of STAT5 by SH-4-54 is not highly effective by itself
in inhibiting neuroblastoma cell proliferation in vitro regardless of whether UBE4B is depleted.
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The dopamine antagonist pimozide, that also has STAT5 inhibitory activity, has been reported
to have some anti-proliferative effect on SK-N-AS (169). In addition , STAT5 and STAT3
have very similar roles in promoting signals for cancer proliferation (190), and there are several
examples of STAT3 inhibitors used as a single agent (197) or in combination with a Jak
inhibitor to successfully reduce neuroblastoma proliferation in vitro and tumor growth in vivo
(198). Even though STAT3 levels were lower in these model cells depleted of UBE4B, these
examples provided an indication that STAT5 inhibition might be able to inhibit neuroblastoma
cell growth. Doing so, however, might require a combination with another antiproliferative
agent.

7.5 UBE4B Depletion Enhances Sensitivity to Cetuximab, an anti-EGFR antibody

Our data demonstrate that the chemotherapy resistant neuroblastoma cell line SK-N-AS
is more sensitive to Cetuximab-mediated EGFR inhibition than the tyrosine kinase inhibitor
erlotinib. The growth inhibitory effect of Cetuximab suggests that at least some of the nondegraded EGFR is located on the cell surface where it can be targeted by Cetuximab.
Furthermore, the maximum Cetuximab dose used in a clinical trial with children having solid
tumors was 250 mg/m (76), which equates to a serum concentration of less than 1 µM based
2

on the average body mass and blood volume of an 18-month-old child (199). Thus, the
Cetuximab concentrations used in this study may be in the therapeutic range for patients whose
tumor cytology indicates low protein levels of UBE4B.
Erlotinib is a small molecule that binds to the intracellular tyrosine kinase domain of
EGFR to prevent enzymatic function (200). It was used here as a control and an alternative
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method of targeting EGFR. Our past cell growth assays with this drug agent have shown it to
be ineffective slowing the growth of the neuroblastoma SK-N-AS line (data not shown).
However, other studies have reported a 4 µM IC for erlotinib in wild type SK-N-AS
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neuroblastoma cells in vitro (91), and a phase I clinical trial with erlotinib has shown efficacy
in patients (201). It is unclear why erlotinib was not effective at inhibiting growth in this study.
Gefitinib, which also targets the tyrosine kinase activity of EGFR, is not effective at inhibiting
neuroblastoma proliferation (202). One explanation for the non-response to erlotinib may be
that STAT5 activation specifically reduces sensitivity to erlotinib in other cancers (83).
However, this still does not explain the similar behavior between wild type and UBE4B
depleted cells since the non-depleted cells would be expected to have a growth inhibitory
effect. It will be worth repeating this experiment with a new preparation of erlotinib and low
passage SK-N-AS cells in the future to determine whether SK-N-AS is in fact non-responsive
to erlotinib. Neuroblastoma is very heterogeneous, which affects the chemotherapy response
(181), and long durations of cell passages in vitro could generate a cell population that is nonresponsive to erlotinib.

7.6 Combination of STAT5 and EGFR Inhibition Reduces Neuroblastoma Growth, Promotes
Apoptosis, and Reduces Migration In Vitro

Our data suggest that combined EGFR and STAT5 inhibition results in decreased
neuroblastoma cell growth and increased apoptotic cell death. This finding parallels a study in
chronic myelogenous leukemia (CML), that indicated high STAT5 levels mediated resistance
to a small molecule tyrosine kinase inhibitors (189), and another study suggesting that EGFR
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blockade combined with Jak/STAT pathway inhibition was highly effective in epidermoid
carcinoma (174). This combination therapy targets the EGFR to prevent ligand binding, reduce
Jak/STAT signaling, and promote receptor degradation (Figure 17) (190). Cetuximab is
unlikely to saturate all of the EGFR on a cell’s surface in vitro because of competitive
inhibition with the ligand EGF (203), and small amounts of antibody actually reach tumors in
vivo (204, 205). Therefore, dual inhibition of the receptor and one of its pathways may
potentiate the effect of Cetuximab to achieve a more robust antiproliferative effect in vitro
(Figure 15) (175). Cells expressing greater levels of EGFR, potentially on the cell surface,
would have more targets for Cetuximab binding to promote cell death. Thus, this targets a proproliferative phenotype of increased levels of EGFR to provide an additional treatment
approach for neuroblastoma.
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Figure 17. Combined EGFR and STAT5 blockade potentiates the effect of
Cetuximab
Cetuximab, an EGFR-specific antibody, binds to the EGFR on the surface of
neuroblastoma to prevent ligand binding and induce receptor degradation. SH-4-54,
a STAT5 inhibitor, blocks one of the pathways of EGFR proliferative signaling. The
combined effect was observed to be greater than either agent alone.

In addition to halting cell growth, there was evidence that the combination therapy also
caused cell death. We observed decreased cell viability with the MTT assay at 72 hours when
compared to the 24- and 48-hour time points, and microscopic examination suggested that cells
were less adherent and dense at longer time points (data not shown). STAT5 normally activates
anti-apoptotic pathways in cancer, and other studies have used a STAT5 null cell line to
significantly enhance the apoptosis induction by a tyrosine kinase inhibitor (189). I found a
significant increase in apoptosis when cells we treated with a combination of the STAT5
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inhibitor SH-4-54 and the EGFR inhibitor Cetuximab, but there was no statistical difference
between UBE4B depleted neuroblastoma cells and the control cells. EGFR inhibition with
Cetuximab can cause cell death by autophagy in addition to apoptosis, especially when there
are high levels of the autophagy-related gene (Atg) proteins (206). In the RPPA dataset, we
saw a four-fold increase in Atg3 in SK-N-AS cells depleted of UBE4B (Figure 11). This may
indicate that death in cells treated with Cetuximab and the STAT5 inhibitor SH-4-54 is
occurring as a result of autophagy more so than apoptosis, especially in cells depleted of
UBE4B.
Migratory behavior of tumor cells is one of the early signs of metastatic spread of cancer
(170, 207), and metastasis to distant sites in the body is a hallmark of more advanced
neuroblastoma disease (12). The epidermal growth factor receptor is also a key driver of wound
healing on the skin, which is a migratory behavior of cells (208). We found that in UBE4Bdepleted neuroblastoma cells, treatment with EGFR and STAT5 inhibitors reduced transwell
migration of the cancer cells in vitro. EGFR inhibition in glioma cells reduces migration in a
similar manner (209). Given that about 70% of neuroblastoma patients have experienced
metastatic disease at the time of initial diagnosis (7), this is an exciting finding requiring further
examination. One pitfall to our present data is that it may not have appropriately taken into
account cell death caused by the combination treatment. Pre-treated cells were counted with
trypan blue, and the number of cells added to the transwell insert for migration experiments
was based off of the number of live cells measured by that reagent. Trypan blue would not take
into account the number of cells on the verge of death, however, so there may have been cells
that failed to migrated because of death alone. An alternative method to both count the cells
and assess viability before the migration assay would be to use flow cytometry with cell sorting

67

(FACS). In summary, these data indicate that in neuroblastoma cells expressing low amounts
of UBE4B, a combination of a STAT5 inhibitor and Cetuximab can inhibit proliferation,
induce cell death, and prevent cell migration that could lead to metastasis.

7.7 Summary and Implications for Treatment

We have observed that depletion of UBE4B can lead to increases in the levels of
proteins involved in proliferation, including EGFR and STAT5a. EGFR inhibition using
Cetuximab has growth inhibitory effects in UBE4B-depleted neuroblastoma cells at lower
concentrations than has been seen previously in wild type cells (18). Finally, EGFR and
STAT5 dual inhibition reduced proliferation, induced apoptosis, and slowed cell migration in
UBE4B-depleted neuroblastoma cells more than either agent alone.
Patients with refractory neuroblastomas often have fewer chemotherapeutic options.
Their care team must rely on salvage chemotherapy, repeat autologous stem cell
transplantation, radiotherapy, or immunotherapy to save the patient’s life (179, 210). The novel
combination of EGFR and STAT5 inhibition described here may provide an additional option
for refractory patients with a 1p36 deletion and lower levels of UBE4B. Given that surgical
resection is the common first step for many neuroblastomas, it would be possible to measure
UBE4B protein levels in patient tumors to determine whether they would be appropriate
candidates.

68

7.8 Future Directions

Orthotopic Animal Experiments
One of the most critical areas for further exploration for this project will be to perform
an in vivo experiment to test the antiproliferative effect of a combination of Cetuximab and the
STAT5 inhibitor SH-4-54 in vivo. An orthotopic xenograft model of neuroblastoma would be
an appropriate model (211). Introduction of luciferase would enable tumor size tracking and
modification of the UBE4B-depleted SK-N-AS cells to express luciferase would allow
examination of tumor responses to EGFR and STAT5 treatments.
Given the anti-proliferative, pro-apoptotic, and anti-migratory effect seen in the model
neuroblastoma line in response to a combination treatment, we hypothesize that in vivo tumors
grown from neuroblastoma cells with a depletion of UBE4B and then treated with this
combination will have less tumor volume over a 5-week experiment, and they may also have
lower incidence of metastasis. In this experiment we would monitor tumor volume with IVIS
as well as body weight and survival time. Following sacrifice we would weigh the excised
tumors and perform immunoblotting for levels if UBE4B, EGFR, STAT5 as well as histologic
analysis for CD31 to assess angiogenesis (212).
Neuroblastoma patients with a deletion at the 1p36 chromosomal location would
potentially be responsive to EGFR and STAT5 inhibition as a form of treatment. About onethird of neuroblastoma patients have this deletion in their cancer cells (14, 19). UBE4B levels
could be tested in surgically resected tumors. Lower levels of UBE4B might indicate using this
novel treatment approach, whereas it might be contraindicated in patients with tumors
containing high levels of UBE4B. This kind of customized therapy for cancer patients is the
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emerging wave of the future (213). Even though neuroblastoma is a relatively rare cancer and
the number of patients treated in this manner would be potentially small, it could improve
survival outcomes for certain high-risk patients. For those patients and their families, this could
be incredibly important.

Assessment of Additional EGFR and Signaling Pathway Combined Treatments
We focused on STAT inhibition here because of the elevated STAT5 and decreased
STAT3 protein levels, which the literature indicated would make these model cells ideal for
treatment with an EGFR and STAT inhibitor (171). Despite this, there are several examples
in the literature where the AKT/PI3K pathway (214) or the MAPK/ERK (215) pathway have
been targeted in neuroblastoma. Future studies could assess the growth inhibitory effects of
those agents in these model cells when combined with Cetuximab.
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